Kemwell Biopharma Signs a Development and Manufacturing Agreement With a European Company for Innovative Monoclonal Antibody Therapeutics

BANGALORE, September 18, 2013 /PRNewswire/ --

Kemwell Biopharma, a global contract development and manufacturing service provider announced today, that it has signed an agreement with a European company for the development and manufacture of monoclonal antibody therapeutics. Kemwell will provide a fully integrated solution including technology transfer, process industrialization, scale-up, manufacturing of toxicology materials, cGMP manufacturing of clinical materials and commercial manufacturing for both drug substance and fill & finish in vials from Kemwell's new state-of-the-art biopharmaceuticals facility in Bangalore, India.

"This broad development and manufacturing agreement demonstrates our customers' confidence in Kemwell's biotechnical capabilities. Partnering with a number of well-known technology providers, Kemwell aims to establish itself as a leading player in the one-stop-shop biopharmaceutical contract manufacturing space. Our endeavor is to capitalize on the eastern advantage of a cost-friendly environment while offering all the western advantages of quality and innovation. Our over 30-year expertise in the pharmaceutical development and manufacturing space will help us provide high quality services and products at competitive prices to the biotech industry. We are also expecting an inspection from a European agency for our biopharmaceutical drug substance as well as fill-finish facility, during the second half of this year," says Kemwell's Managing Director, Anurag Bagaria.

In 2008, Kemwell entered into a strategic collaboration with Boehringer Ingelheim, Germany. These facilities have been designed with the engineering and operational support of Boehringer Ingelheim. Kemwell's biotechnology capabilities now include process development and manufacturing of drug substances and drug products for toxicology in 80L scale bioreactors, as well as for cGMP clinical and commercial manufacturing in 400L and 2000L bioreactors with corresponding downstream processing, fill & finish in liquid and lyophilized vials and integrated quality management.

About Kemwell Biopharma

Kemwell Biopharma Pvt Ltd with its head office in Bangalore, India is a pure play contract development and manufacturing company. The company develops and manufactures bio/pharmaceuticals for some of the world's top pharmaceutical companies, including Bayer, Boehringer Ingelheim, GlaxoSmithKline, Merck KGaA, Novartis, and Pfizer. Kemwell is one of India's largest CDMO of bio/pharmaceuticals with over 30 years' experience. The company employs more than 1200 employees worldwide and has seven production facilities and state-of-the art research and development laboratories in India and Sweden. Kemwell is an approved bio/pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian markets.

Read more about Kemwell on www.kemwellbiopharma.com 

Primary Media Contact: Karan Bagaria, [email protected], 91-80-39286200

Secondary Media Contact: Nicholas Mccray, [email protected], 1-985-2901315